Combination therapy of anti-mif antibodies and chemotherapeutics

摘要

Discloses the use of an anti-MIF antibody in combination with a chemotherapeutic agent in the manufacture of a medicament for treating ovarian or prostate cancer in a subject. The antibody is specific for the oxidized form of Macrophage inhibitory factor (oxMIF) rather than the reduced form (redMIF) and is selected from RAM9, RAM0, RAB9 and RAB0. Examples of chemotherapeutic agents used are gemcitabine, cisplatin, mitoxantrone and doxorubicin. Examples illustrate use against models of pancreatic, ovarian and prostate cancer.